Winfield Associates’s AbbVie ABBV Stock Holding History

Winfield Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-960	Closed	-$94K	–	123
2017 Q4	$94K	Hold	960	–	–	0.05%	153
2017 Q3	$85K	Hold	960	–	–	0.04%	155
2017 Q2	$70K	Hold	960	–	–	0.04%	163
2017 Q1	$62K	Hold	960	–	–	0.04%	173
2016 Q4	$61K	Buy	960 +90	+10%	+$5.49K	0.04%	168
2016 Q3	$55K	Sell	870 -1,049	-55%	-$67.9K	0.03%	166
2016 Q2	$119K	Sell	1,919 -110	-5%	-$6.7K	0.08%	132
2016 Q1	$116K	Sell	2,029 -3,840	-65%	-$214K	0.08%	125
2015 Q4	$348K	Sell	5,869 -600	-9%	-$34.6K	0.23%	78
2015 Q3	$352K	Sell	6,469 -1,805	-22%	-$117K	0.26%	81
2015 Q2	$556K	Hold	8,274	–	–	0.38%	68
2015 Q1	$484K	Sell	8,274 -4,651	-36%	-$281K	0.34%	73
2014 Q4	$846K	Sell	12,925 -300	-2%	-$18.9K	0.62%	49
2014 Q3	$764K	Buy	13,225 +144	+1%	+$8K	0.57%	57
2014 Q2	$738K	Sell	13,081 -1,997	-13%	-$105K	0.53%	61
2014 Q1	$775K	Sell	15,078 -12,781	-46%	-$646K	0.64%	50
2013 Q4	$1.47M	Buy	+27,859	New	+$1.37M	1.21%	21

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Winfield Associates's ABBV Position: Q1 2018 in Review

Winfield Associates sold out of AbbVie (ABBV) in Q1 2018, closing a stake of 960 shares — an estimated $94K sold.

Winfield Associates first reported a position in ABBV in Q4 2013 and held it in 17 quarters. The position peaked at $1.47M in Q4 2013. 2,016 funds tracked by Wall St. Rank hold ABBV as of Q1 2018.

Winfield Associates reported no remaining AbbVie position as of Q1 2018 after selling out during the quarter.
Winfield Associates sold 960 AbbVie shares in Q1 2018, an estimated $94K.
Winfield Associates first reported a position in AbbVie in Q4 2013 and held it in 17 quarters.
Winfield Associates's AbbVie position peaked at $1.47M in Q4 2013.
2,016 funds tracked by Wall St. Rank held AbbVie as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.